Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rituximab - Biogen Idec/Genentech

X
Drug Profile

Rituximab - Biogen Idec/Genentech

Alternative Names: IDEC-102; IDEC-C2B8; IDEC-C2B8-anti-CD20; MabThera; R 105; RG 105; Ristova; Rituxan; Rituximab-EU; RO-452294

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec
  • Developer AstraZeneca; Biogen; Biogen Idec; Cambridge University Hospitals; Cedars-Sinai Medical Center; Celgene Corporation; Chugai Pharmaceutical; Genentech; Hackensack University Medical Center; Hoosier Cancer Research Network; Janssen Research & Development; M. D. Anderson Cancer Center; Mayo Clinic; Nagoya University; Oregon Health & Science University; Roche; SCRI Development Innovations; Takeda Oncology; University of Pennsylvania; University of Texas M. D. Anderson Cancer Center; University of Tours; Zenyaku Kogyo
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pemphigus vulgaris; Idiopathic thrombocytopenic purpura; Thrombotic thrombocytopenic purpura; Microscopic polyangiitis; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Nephrotic syndrome; Granulomatosis with polyangiitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Follicular lymphoma; Granulomatosis with polyangiitis; Idiopathic thrombocytopenic purpura; Lymphoproliferative disorders; Microscopic polyangiitis; Nephrotic syndrome; Non-Hodgkin's lymphoma; Pemphigus vulgaris; Rheumatoid arthritis
  • Registered Neuromyelitis optica; Systemic scleroderma; Thrombotic thrombocytopenic purpura
  • Preregistration Diffuse large B cell lymphoma
  • Phase III Anti-neutrophil cytoplasmic antibody-associated vasculitis; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Transplant rejection
  • Phase II B-cell lymphoma; Chronic inflammatory demyelinating polyradiculoneuropathy; Glomerulonephritis; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Renal transplant rejection
  • No development reported Multiple myeloma; Multiple sclerosis; Ocular inflammation; Primary biliary cirrhosis; Scleritis; Sjogren's syndrome; Ulcerative colitis
  • Discontinued Dermatomyositis; Graft-versus-host disease; Lupus nephritis; Systemic lupus erythematosus

Most Recent Events

  • 08 Jun 2023 Updated adverse events and efficacy data from a phase II trial in Diffuse large B cell lymphoma presented at the 28th Congress of the European Haematology Association (EHA-2023)
  • 08 Jun 2023 Efficacy and adverse events data from a phase III trial in Chronic lymphocytic leukaemia presented at the 28th Congress of the European Haematology Association (EHA-2023)
  • 02 Jun 2023 Efficacy data from a phase II trial in Acute lymphoblastic leukemia presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top